Skip to Content

Join the 'Effient' group to help and get support from people like you.

Effient News

Sickle Cell Drug Doesn't Relieve Pain Crises: Study

Posted 8 Dec 2015 by Drugs.com

TUESDAY, Dec. 8, 2015 – The anti-clotting drug prasugrel does little to reduce the risk of pain crises in children with sickle cell disease, a new study shows. The research included 341 patients in 13 countries in Africa, the Americas, Asia, Europe and the Middle East. About half took prasugrel (Effient) for between nine and 24 months. The other half took a placebo. There was little difference between the two groups in rates of pain crises caused by interrupted blood flow in small blood vessels, the scientists found. Over time, repeated pain crises lead to tissue damage and chronic inflammation. The study was led by researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and University of California, San Francisco's Benioff Children's Hospital Oakland. "Although we were disappointed that prasugrel does not appear to ease the suffering of children with sickle cell ... Read more

Related support groups: Pain, Effient, Hydroxyurea, Hydrea, Anemia - Sickle Cell, Prasugrel, Droxia, Mylocel

Wide Variations Seen in U.S. Stroke Care

Posted 7 Jul 2015 by Drugs.com

TUESDAY, July 7, 2015 – Americans' odds of receiving a drug that can halt strokes in progress may vary widely depending on their ZIP codes, a new study finds. Experts said the findings, reported in the July issue of the journal Stroke, help verify what everyone has suspected: There are disparities in emergency stroke care across the United States, specifically in the use of a clot-busting drug called tissue plasminogen activator, or tPA. And the magnitude of the disparities was "striking," said senior researcher Dr. James Burke, of the University of Michigan in Ann Arbor. In 20 percent of hospital markets, not a single stroke patient received tPA over four years, Burke's team found. In others, up to 14 percent of stroke patients received the drug. The big question is: Why? "We really don't know what's driving this," Burke said. The hospital markets that most often gave tPA were ... Read more

Related support groups: Aspirin, Plavix, Ischemic Stroke, Clopidogrel, Transient Ischemic Attack, Effient, Aggrenox, Brilinta, Ischemic Stroke - Prophylaxis, Ecotrin, Cilostazol, Pletal, Bayer Aspirin, Thromboembolic Stroke Prophylaxis, Dipyridamole, Prasugrel, Ticagrelor, Persantine, Bufferin, Activase

Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study

Posted 17 Nov 2014 by Drugs.com

MONDAY, Nov. 17, 2014 – Heart attack and stroke patients can safely take aspirin combined with a blood-thinning medication, new research confirms. The blood-thinning combination won't increase a patient's risk of early death, according to a new study presented Sunday at the annual meeting of the American Heart Association in Chicago. The report was also published online Nov. 16 in The Lancet. Analysis of data from more than a dozen clinical trials revealed no increase in death rate if heart patients took both drugs together for long periods of time, said study co-author Dr. Laura Mauri, an associate professor of cardiovascular medicine at Harvard Medical School in Boston. "Patients should not be afraid of taking these medications," Mauri said. "In fact, it's important they continue to take them as directed, because they can be life-saving." The U.S. Food and Drug Administration issued ... Read more

Related support groups: Aspirin, Plavix, Clopidogrel, Effient, Ecotrin, Bayer Aspirin, Prasugrel, Bufferin, Low Dose ASA, Aspergum, Buffered Aspirin, Fasprin, Ascriptin, St Joseph Aspirin, Easprin, ZORprin, Aspir-Low, Sloprin, Aspirin Low Strength, Acetylsalicylic Acid

FDA Medwatch Alert: Long-term Antiplatelet Therapy: Safety Announcement - Preliminary Trial Data Shows Benefits But a Higher Risk of Non-Cardiovascular Death

Posted 16 Nov 2014 by Drugs.com

[Posted 11/16/2014] ISSUE: FDA is evaluating preliminary data from a clinical trial showing that treatment for 30 months with dual antiplatelet blood-thinning therapy decreased the risk of heart attacks and clot formation in stents, but there was an increased overall risk of death compared to 12 months of treatment. The clinical trial compared 30 months versus 12 months of treatment with dual antiplatelet therapy consisting of aspirin plus either clopidogrel (Plavix) or prasugrel (Effient), following implantation of drug-eluting coronary stents. These stents are small, medicine-coated tubes inserted into narrowed arteries in the heart to keep them open and maintain blood flow to the heart. Clopidogrel and prasugrel are important medicines used to prevent heart attacks, strokes, and other clot-related diseases.  FDA believes the benefits of clopidogrel (Plavix) and prasugrel (Effient) ... Read more

Related support groups: Plavix, Clopidogrel, Effient, Prevention of Thromboembolism in Atrial Fibrillation, Prasugrel

Standard Dose of Blood Thinner May Not Be Best for All Patients

Posted 6 Nov 2012 by Drugs.com

TUESDAY, Nov. 6 – Seventy-five percent of patients taking the widely used blood thinners clopidogrel (Plavix) and prasugrel (Effient) are getting the incorrect dose and could be at risk for serious problems such as uncontrolled bleeding or blood clots, a new study contends. Millions of Americans with coronary artery disease take the drugs to prevent blood clots that could cause a heart attack or stroke. Guidelines recommend that all patients take the same standardized dose, but that dose is not effective for all patients, according to researchers at the Intermountain Medical Center Heart Institute in Salt Lake City. The researchers looked at more than 500 patients and found that half of patients taking Plavix were getting too little of the drug to most effectively prevent blood clots, while a quarter were getting too much. Only a quarter were receiving an appropriate dose. Among ... Read more

Related support groups: Plavix, Clopidogrel, Effient, Coronary Artery Disease (CAD), Prasugrel

New Blood Thinner Effient No Better Than Plavix at Preventing Heart Trouble: Study

Posted 26 Aug 2012 by Drugs.com

SUNDAY, Aug. 26 – The newer blood thinner Effient is no more effective than the widely used Plavix in preventing death, heart attacks or strokes, new research finds. Nor is Effient (prasugrel) any safer than Plavix (clopidogrel) when it comes to bleeding complications in patients with acute coronary syndrome who have not had revascularization procedures such as bypass surgery or stenting. The findings are scheduled to be presented Sunday at the European Society of Cardiology annual meeting in Munich and simultaneously published online in the New England Journal of Medicine. The study was funded by Eli Lilly and Co. and Daiichi Sankyo Co., which co-developed Effient. Acute coronary syndrome (ACS) includes heart attacks and other conditions, such as angina, which result from blocked coronary arteries. Roughly 60 percent of patients with ACS undergo revascularization procedures to restore ... Read more

Related support groups: Plavix, Heart Attack, Clopidogrel, Effient, Myocardial Infarction, Ischemic Stroke - Prophylaxis, Prasugrel

Guidelines Issued for New Blood Thinner Brilinta

Posted 16 Jul 2012 by Drugs.com

MONDAY, July 16 – The new blood-thinning drug Brilinta should be considered along with older drugs to treat patients with unstable angina, according to updated guidelines. Unstable angina occurs when a partially blocked coronary artery deprives the heart of blood and oxygen. The updated guidelines were issued jointly by the American Heart Association Task Force on Practice Guidelines and the American College of Cardiology Foundation. "We have put it on equal footing with two other [blood-thinning] medications: clopidogrel (Plavix) and prasugrel (Effient)," lead author Dr. Hani Jneid, assistant professor of medicine and director of interventional cardiology research at Baylor College of Medicine in Houston, said in an American Heart Association news release. The new guidelines state that Brilinta (ticagrelor), which was approved by the U.S. Food and Drug Administration in 2011, should ... Read more

Related support groups: Plavix, Angina, Clopidogrel, Effient, Brilinta, Prasugrel, Ticagrelor

Rx for Heart Patients: Healthier Living, Medication

Posted 3 Nov 2011 by Drugs.com

THURSDAY, Nov. 3 – A healthy lifestyle and appropriate medications can help people with heart disease live longer and avoid a heart attack or stroke, according to new guidelines from the American College of Cardiology Foundation and the American Heart Association. Following the updated recommendations can also improve quality of life, reduce the need for surgical procedures to open blocked arteries and lower the likelihood of a repeat heart attack or stroke if you've suffered one already, the authors said. "The full implementation of these cardiovascular protective therapies into clinical practice can markedly reduce the risk of death, disability and health care expenditures due to cardiovascular disease," said Dr. Gregg Fonarow, professor of cardiology at the University of California, Los Angeles and a spokesman for the American Heart Association. For the first time, the guidelines ... Read more

Related support groups: Aspirin, Heart Disease, Plavix, Smoking, Ischemic Stroke, Heart Attack, Smoking Cessation, Clopidogrel, Effient, Myocardial Infarction, Brilinta, Prevention of Cardiovascular Disease, Ecotrin, Bayer Aspirin, Prasugrel, Ticagrelor, FluLaval, Afluria, Bufferin, Fluzone

Ask a Question

Further Information

Related Condition Support Groups

Acute Coronary Syndrome

Effient Patient Information at Drugs.com